Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder
Autore:
Cook, EH; Wagner, KD; March, JS; Biederman, J; Landau, P; Wolkow, R; Messig, M;
Indirizzi:
Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA Univ Chicago Chicago IL USA 60637 o, Dept Psychiat, Chicago, IL 60637 USA Univ Chicago, Dept Pediat, Chicago, IL 60637 USA Univ Chicago Chicago IL USA 60637 ago, Dept Pediat, Chicago, IL 60637 USA Univ Texas, Med Branch, Div Child & Adolescent Psychiat, Galveston, TX 77550 USA Univ Texas Galveston TX USA 77550 scent Psychiat, Galveston, TX 77550 USA Duke Univ, Med Ctr, Durham, NC USA Duke Univ Durham NC USADuke Univ, Med Ctr, Durham, NC USA Massachusetts Gen Hosp, Dept Psychiat, Pediat Pharmacol Unit, Boston, MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 col Unit, Boston, MA 02114 USA Harvard Univ, Sch Med, Boston, MA USA Harvard Univ Boston MA USAHarvard Univ, Sch Med, Boston, MA USA Pfizer Inc, New York, NY USA Pfizer Inc New York NY USAPfizer Inc, New York, NY USA
Titolo Testata:
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
fascicolo: 10, volume: 40, anno: 2001,
pagine: 1175 - 1181
SICI:
0890-8567(200110)40:10<1175:LSTOCA>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONTROLLED TRIAL; PLACEBO; CLOMIPRAMINE; MULTICENTER; SCALE; EPIDEMIOLOGY; OUTPATIENTS; RELIABILITY; VALIDITY;
Keywords:
sertraline; obsessive-compulsive disorder;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Cook, EH Univ Chicago, Dept Psychiat, MC 3077,5841 S Maryland Ave, Chicago, IL 60637 USA Univ Chicago MC 3077,5841 S Maryland Ave Chicago IL USA 60637 USA
Citazione:
E.H. Cook et al., "Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder", J AM A CHIL, 40(10), 2001, pp. 1175-1181

Abstract

Objective: To evaluate the safety and effectiveness of sertraline in the long-term treatment of pediatric obsessive-compulsive disorder (OCD). Method: Children (6-12 years; n = 72) and adolescents (13-18 years n = 65) with DSM-III-R-defined OCD who had completed a 12-week, double-blind, placebo-controlled sertraline study were given open-label sertraline 50 to 200 mg/day in this 52-week extension study Concomitant psychotherapy was allowed during the extension study. Outcome was evaluated by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), National Institute of Mental Health Global Obsessive-Compulsive Scale, and Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores. Results: Significant improvement (p <.0001) was demonstrated on all four outcome parameters on an intent-to-treat analysis for the overall study population (n = 132), as well as the child and the adolescent samples. At endpoint, 72% of children and 61 % of adolescents met response criteria (<greater than>25% decrease in CY-BOCS and a CGI-I score of 1 or 2). Significant (p < .05) improvements were also demonstrated from the extension study baseline to endpoint on all outcome parameters in those patients who received sertraline during the 12-week, double-blind acute study. Long-term sertraline treatment was well tolerated, and there were no discontinuations; due to changes in vital signs, laboratory values, or electrocardiograms. Conclusion: Sertraline (50-200 mg/day) was effective and generally well tolerated in the treatment of childhood and adolescent OCD for up to 52 weeks. Improvement was seen with continued treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 23:27:04